Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1971 1
1972 3
1973 3
1974 5
1975 13
1976 7
1977 5
1978 10
1979 8
1980 8
1981 2
1982 4
1983 4
1984 2
1985 3
1986 2
1987 5
1988 6
1989 3
1990 7
1991 4
1992 4
1993 6
1994 7
1995 8
1996 10
1997 7
1998 10
1999 5
2000 5
2001 11
2002 13
2003 7
2004 15
2005 11
2006 7
2007 5
2008 10
2009 21
2010 10
2011 5
2012 6
2013 4
2014 6
2015 6
2016 3
2017 4
2018 4
2019 4
2020 2
2021 2
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

314 results

Results by year

Filters applied: . Clear all
Page 1
Can LDL cholesterol be too low? Possible risks of extremely low levels.
Olsson AG, Angelin B, Assmann G, Binder CJ, Björkhem I, Cedazo-Minguez A, Cohen J, von Eckardstein A, Farinaro E, Müller-Wieland D, Parhofer KG, Parini P, Rosenson RS, Starup-Linde J, Tikkanen MJ, Yvan-Charvet L. Olsson AG, et al. J Intern Med. 2017 Jun;281(6):534-553. doi: 10.1111/joim.12614. J Intern Med. 2017. PMID: 28295777 Free article. Review.
Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab.
Hagström E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, Diaz R, Goodman SG, Harrington RA, Jukema JW, Liberopoulos E, Marx N, McGinniss J, Manvelian G, Pordy R, Scemama M, White HD, Zeiher AM, Schwartz GG; ODYSSEY OUTCOMES Investigators. Hagström E, et al. Circulation. 2022 Aug 30;146(9):657-672. doi: 10.1161/CIRCULATIONAHA.121.057807. Epub 2022 Jun 30. Circulation. 2022. PMID: 35770629 Free PMC article. Clinical Trial.
Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.
Willeit P, Ridker PM, Nestel PJ, Simes J, Tonkin AM, Pedersen TR, Schwartz GG, Olsson AG, Colhoun HM, Kronenberg F, Drechsler C, Wanner C, Mora S, Lesogor A, Tsimikas S. Willeit P, et al. Among authors: olsson ag. Lancet. 2018 Oct 13;392(10155):1311-1320. doi: 10.1016/S0140-6736(18)31652-0. Epub 2018 Oct 4. Lancet. 2018. PMID: 30293769 Free article.
Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial.
Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Schwartz GG, et al. Among authors: olsson ag. JAMA. 2001 Apr 4;285(13):1711-8. doi: 10.1001/jama.285.13.1711. JAMA. 2001. PMID: 11277825 Clinical Trial.
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial.
Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg PG; ODYSSEY OUTCOMES Committees and Investigators. Ray KK, et al. Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628. doi: 10.1016/S2213-8587(19)30158-5. Epub 2019 Jul 1. Lancet Diabetes Endocrinol. 2019. PMID: 31272931 Free article. Clinical Trial.
Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol.
Schwartz GG, Szarek M, Bittner VA, Diaz R, Goodman SG, Jukema JW, Landmesser U, López-Jaramillo P, Manvelian G, Pordy R, Scemama M, Sinnaeve PR, White HD, Gabriel Steg P; ODYSSEY Outcomes Committees and Investigators. Schwartz GG, et al. J Am Coll Cardiol. 2021 Aug 3;78(5):421-433. doi: 10.1016/j.jacc.2021.04.102. J Am Coll Cardiol. 2021. PMID: 34325831 Free PMC article. Clinical Trial.
Regression of femoral atherosclerosis.
Olsson AG. Olsson AG. Circulation. 1991 Feb;83(2):698-700. doi: 10.1161/01.cir.83.2.698. Circulation. 1991. PMID: 1991386 Clinical Trial. No abstract available.
Synvinolin in hypercholesterolaemia.
Olsson AG, Mölgaard J, von Schenk H. Olsson AG, et al. Lancet. 1986 Aug 16;2(8503):390-1. doi: 10.1016/s0140-6736(86)90070-x. Lancet. 1986. PMID: 2874382 Clinical Trial. No abstract available.
RE: Praluent (Alirocumab)-Induced Renal Injury.
Rosenson RS, Larrey D, Waters DD, Olsson AG; Members of the Phase 3 Data Monitoring Committee for PRALUENT. Rosenson RS, et al. Among authors: olsson ag. J Pharm Pract. 2018 Apr;31(2):138-139. doi: 10.1177/0897190017734429. Epub 2017 Oct 3. J Pharm Pract. 2018. PMID: 28974137 Free PMC article. No abstract available.
314 results